King Abdullah International Medical Research Center
Quick facts
Marketed products
- low-dose epinephrine and tranexamic acid · Trauma, Hemorrhage, Critical Care
Low-dose epinephrine stimulates adrenergic receptors to increase heart rate and blood pressure, while tranexamic acid inhibits fibrinolysis to reduce bleeding. - Nilotinib 300 mg. · Oncology
Nilotinib is a tyrosine kinase inhibitor that selectively blocks BCR-ABL and other kinases to inhibit abnormal cell proliferation in chronic myeloid leukemia. - Nucleos(t)tide analogues · Virology / Infectious Disease
Nucleos(t)ide analogues inhibit viral reverse transcriptase and/or polymerase enzymes, preventing viral nucleic acid synthesis and replication.
Phase 3 pipeline
- Leukotriene Receptor Antagonist · Respiratory / Immunology
Leukotriene receptor antagonists block cysteinyl leukotriene receptors on airway and immune cells, reducing inflammatory mediator signaling.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- King Abdullah International Medical Research Center portfolio CI brief
- King Abdullah International Medical Research Center pipeline updates RSS
Frequently asked questions about King Abdullah International Medical Research Center
What are King Abdullah International Medical Research Center's marketed drugs?
Top marketed products include low-dose epinephrine and tranexamic acid, Nilotinib 300 mg., Nucleos(t)tide analogues.
What is King Abdullah International Medical Research Center's pipeline?
King Abdullah International Medical Research Center has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Leukotriene Receptor Antagonist.
Related
- low-dose epinephrine and tranexamic acid · Trauma, Hemorrhage, Critical Care
- Nilotinib 300 mg. · Oncology
- Nucleos(t)tide analogues · Virology / Infectious Disease
- Sector hub: All tracked pharma companies